Compare Organon & Co. Common Stock (OGN) vs TKO Group Holdings Inc (TKO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Organon & Co. Common Stock vs TKO Group Holdings Inc — how do they compare? Organon & Co. Common Stock trades at $13.58 (market cap $3.62B), while TKO Group Holdings Inc trades at $173.56 (market cap $12.71B). The key difference: TKO Group Holdings Inc is far larger — about 3.5× Organon & Co. Common Stock's market cap, and TKO Group Holdings Inc pays the higher dividend (1.82%). Which is the better fit depends on your goals — on Pluang, investors hold Organon & Co. Common Stock for 0 Days and TKO Group Holdings Inc for 31 Days on average.
| OGN | TKO | |
|---|---|---|
Market Cap | $3.62B | $12.71B |
Volume | 2,892,999 | 835,872 |
Sector | Health | Media |
52-Week High | $13.81 | $224.96 |
52-Week Low | $5.70 | $172.38 |
Typical Hold Time | 0 Days | 31 Days |
Enterprise Value | $11.04B | $17.07B |
Dividend Yield | 0.58% | 1.82% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Organon (OGN) trades at $13.77, showing no change in the latest session. The stock demonstrates strong profitability with 52.68% gross margins and 24.04% ROE, though recent quarterly earnings have missed expectations. Valuation appears reasonable with P/E of 17.65 and P/S of 0.59. The company shows positive cash flow trends with 2026 projections indicating $533M net cash flow. Recent FDA developments for MIUDELLA and VTAMA products highlight ongoing pipeline progress.
OGN presents a mixed outlook with solid fundamentals offset by earnings misses. The healthcare company's improving cash flow and product pipeline offer potential upside, but investor sentiment remains divided with analysts showing cautious optimism. Key risks include execution challenges and competitive pressures in the pharmaceutical sector.
TKO trades at $173.86, near a 52-week low, with a bearish technical signal. The company reported mixed Q2 2026 earnings, missing EPS estimates but raising full-year guidance. Revenue growth is solid, with 2026 projected at $5.3B, though profitability remains modest with a net margin of 4.33%. Analyst sentiment is overwhelmingly positive, with a consensus price target of $227.00 and 89% buy ratings, but recent institutional selling and technical weakness suggest near-term caution.
The outlook is cautiously optimistic; strong media rights and franchise value underpin long-term growth, but high valuation multiples and recent price decline highlight execution risks. Investors should weigh robust analyst confidence against technical bearishness and margin pressures.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Organon & Co. Common Stock
Organon & Co. is a global healthcare company focused on women's health, biosimilars, and established brands, spun off from Merck & Co. in 2021. Its portfolio of more than 70 medicines includes contraception and fertility therapies, immunology and oncology biosimilars, and treatments in cardiovascular, respiratory, and dermatology, distributed in over 140 countries.
Read more on OGN →About TKO Group Holdings Inc
TKO Group Holdings is a premium sports and entertainment company that serves as the parent entity for the Ultimate Fighting Championship (UFC) and World Wrestling Entertainment (WWE). Formed through a seismic merger orchestrated by Endeavor, TKO leverages a combined global fanbase of over 1 billion to drive massive revenue through media rights, global live events, and a unified sponsorship platform, effectively monopolizing the professional combat sports landscape.
Read more on TKO →
